InspireMD (NSPR) AI Stock Analysis

• Market Cap: $78.98M
• Dividend Yield: N/A
• Average Volume (3M): 59.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 12.96%
• EPS Growth: 33.43%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Devices
• EPS (TTM): -0.78
• Shares Outstanding: 29,689,857
• 10 Day Avg. Volume: 57,501
• 30 Day Avg. Volume: 59,174
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 11.61
• Price to Cash Flow (P/CF): -3.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.00
• Price Target Upside: 95.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

InspireMD faces significant profitability and cash flow challenges despite revenue growth and a solid equity position. Technical indicators suggest weak momentum. The company's valuation metrics highlight profitability issues. The earnings call shows potential growth in the US market, but rising costs and losses remain concerns.

Positive Factors

FDA Approval

FDA approval of InspireMD's CGuard carotid artery stent is a major catalyst for the company.

Market Share

The 30-day DSMI rate for CGuard is sub-1%, supporting a quick share shift to CGuard within the TF-CAS market.

Strategic Acquisition

InspireMD is eventually expected to be acquired by a strategic company.

Negative Factors

Market Competition

InspireMD faces significant competition with other products in the market having DSMI rates ranging from 2.3% to as high as 8.3%.

InspireMD Business Overview & Revenue Model

Company Description

InspireMD, Inc. (NSPR) is a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary diseases. The company's flagship product is the CGuard Embolic Prevention System (EPS), designed to prevent stroke following carotid artery stenting procedures. InspireMD operates in the healthcare sector, specializing in advanced stent systems that address significant clinical needs in the cardiovascular and neurovascular markets.

How the Company Makes Money

InspireMD generates revenue primarily through the sale of its proprietary stent systems, particularly the CGuard Embolic Prevention System. The company sells its products to hospitals, clinics, and medical institutions worldwide, leveraging a network of distributors and direct sales teams. Key revenue streams include product sales, strategic partnerships, and distribution agreements that expand the reach of its stent technologies. InspireMD's earnings are significantly influenced by its ability to obtain regulatory approvals, expand its market presence, and drive adoption of its innovative solutions in the medical community.

InspireMD Financial Statement Overview

Summary

InspireMD demonstrates revenue growth, but faces profitability and cash flow challenges. A strong equity position is offset by operational losses and negative cash flows.

Income Statement

InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.

Cash Flow

InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.01M	6.21M	5.17M	4.50M	2.48M
	Gross Profit
1.51M	1.81M	1.12M	754.00K	83.00K
	EBIT
-33.50M	-21.14M	-18.71M	-14.72M	-10.38M
	EBITDA
-33.50M	-20.91M	-18.52M	-14.55M	-10.39M
	Net Income Common Stockholders
1.56M	-19.92M	-18.49M	-14.92M	-10.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
34.64M	39.02M	17.80M	34.04M	12.64M
	Total Assets
46.81M	47.64M	24.65M	39.71M	17.78M
	Total Debt
1.80M	1.59M	1.61M	1.20M	999.00K
	Net Debt
-17.12M	-8.04M	-3.02M	-10.80M	-11.65M
	Total Liabilities
10.72M	8.14M	7.26M	6.18M	5.61M
	Stockholders Equity
36.09M	39.50M	17.39M	33.53M	12.16M
Cash Flow		Free Cash Flow
-23.27M	-16.76M	-16.02M	-13.55M	-9.17M
	Operating Cash Flow
-21.87M	-16.38M	-15.54M	-13.21M	-9.08M
	Investing Cash Flow
12.64M	-16.09M	8.44M	-22.46M	-187.00K
	Financing Cash Flow
18.45M	37.53M	-140.00K	35.03M	16.39M

InspireMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Negative. The current price of 2.56 is below the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.84, and below the 200-day MA of 2.74, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 32.10 is Neutral, neither overbought nor oversold. The STOCH value of 27.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NSPR.

InspireMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNDM	56 Neutral	$1.13B	―	-33.30%	―	25.74%	57.18%
AXGN	54 Neutral	$704.62M	―	-9.99%	―	17.81%	54.69%
STAA	51 Neutral	$768.00M	55.81	-5.16%	―	-2.64%	-193.31%
ANIK	49 Neutral	$192.79M	―	-20.21%	―	-8.92%	31.98%
IRIX	49 Neutral	$15.92M	―	-153.37%	―	-6.17%	8.27%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
NSPR	44 Neutral	$78.98M	―	-84.68%	―	12.96%	33.43%

InspireMD Corporate Events

InspireMD CFO Retirement Amid Strategic Transition

InspireMD announced the upcoming retirement of its Chief Financial Officer, Craig Shore, after a successor is appointed. Shore, who has contributed significantly to the company’s growth over 15 years, will aid in the transition process. This leadership change comes as the company is poised for potential FDA approval in 2025 and is intensifying its focus on the investment community. InspireMD has initiated a search for a new CFO to continue its trajectory as a global leader in carotid interventions.

InspireMD Advances CGuard Prime with New Clinical Trial

InspireMD, Inc. has enrolled its first patient in the CGUARDIANS II clinical trial, a significant milestone for its CGuard Prime Carotid Stent System used in Transcarotid Artery Revascularization. This study aims to expand the application of this innovative stenting platform, offering improved protection against strokes with a potential FDA approval on the horizon, addressing a growing U.S. market of 30,000 procedures annually.

InspireMD Strengthens Leadership with Scott R. Ward Appointment

InspireMD has appointed Scott R. Ward, a seasoned executive with a rich history in medical technology and a track record of growth and innovation, to its Board of Directors. This strategic move is expected to leverage Ward’s extensive experience in the cardiovascular field as InspireMD gears up for potential U.S. approval of its groundbreaking CGuard Prime stent system, anticipated to set a new standard in carotid intervention and stroke prevention.

InspireMD Achieves Record Q3 Revenue with CGuard Success

InspireMD, Inc. has reported record revenue for Q3 2024, driven by its CGuard Prime carotid stent system, which is moving towards potential U.S. approval. Recent developments include submitting a PMA application to the FDA and receiving IDE approval for pivotal trials. The company anticipates a U.S. commercial launch in early 2025, supported by a new Miami headquarters. Despite increased operating expenses, InspireMD’s strategic advancements position it for growth in the carotid artery disease treatment market.